Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis

Jean-Christophe Lagier1,2, Matthieu Million1,2, Sébastien Cortaredona1,3, Léa Delorme1, Philippe Colson1,2, Pierre-Edouard Fournier1,3, Philippe Brouqui1,2, Didier Raoult1,2, Philippe Parola1,3

On behalf of the IHU Task Force

IHU-Méditerranée Infection, Marseille, France; 2MEPHI, Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique Hôpitaux de Marseille, Marseille, France; 3VITROME, Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique Hôpitaux de Marseille, Service de Santé des Armées, Marseille, France

Correspondence: Philippe Parola, Institut Hospitalo-Universitaire Méditerranée Infection, 19-21 Boulevard Jean Moulin, Marseille, 13005, France, Tel + 33 0 4 13 73 24 01, Fax + 33 0 4 13 73 24 02, Email philippe.parola@univ-amu.fr; Jean-Christophe Lagier, Email jeanchristophe.lagier@ap-hm.fr

Objectives: We evaluated the 6-week mortality of SARS-CoV-2 hospitalized patients treated using a standardized protocol in 2020 in Marseille, France.

Methods: A retrospective monocentric cohort study was conducted in the standard hospital wards at the Institut Hospitalo-Universitaire Méditerranée Infection, between March and December 2020 in adults with SARS-CoV-2 PCR-proven infection.

Results: Of the 2111 hospitalized patients (median age, 67 [IQR 55–79] years; 1154 [54.7%] men), 271 were transferred to the intensive care unit (12.8%) and 239 died (11.3%; the mean age of patients who died was 81.2 (±9.9)). Treatment with hydroxychloroquine plus azithromycin (HCQ-AZ), used in 1270 patients, was an independent protective factor against death (0.68 [0.52 – 0.88]). This effect was consistent for all subgroups of age, comorbidities, severity of the disease and comedications with zinc or corticosteroids. Zinc was independently protective against death (0.39 [0.23 – 0.67]), in a subgroup analysis of patients treated with HCQ-AZ without dexamethasone. The use of high-flow oxygen therapy in elderly patients who were not eligible for intensive care unit transfer saved 19 patients (33.9%).

Conclusions: In our 2020 cohort, treating COVID-19 with HCQ-AZ was associated with lower mortality. These results need to be analyzed in the context of academic discussions about observational studies versus randomized clinical trials. More data will deserve to be analyzed in the SARS-CoV 2 variants, vaccination and post-vaccination era.

Keywords: SARS-CoV-2, COVID-19, hydroxychloroquine, azithromycin

Introduction

By January 17th, 2022, SARS-CoV-2 outbreak had infected 328 million people and killed more than five million people.1

For 2 years, worldwide management of the disease varied significantly in terms of indications for SARS CoV-2 testing of patients, therapeutic options and follow-up. Starting March 2020, and based on preliminary Chinese data,2,3 at our hospital in Marseille, France, we decided upon a strategy including early massive screening by PCR and early treatment with hydroxychloroquine (HCQ) and azithromycin (AZ).4–7

At that time, among the candidate treatments, only four main drugs (remdesivir, lopinavir-ritonavir, HCQ and dexamethasone) had been tested in large randomised studies. Lopinavir-ritonavir and remdesivir were associated with...
several and sometimes severe adverse events but did not demonstrate reproducible clinical efficacy.\(^8\,\,9\) Corticosteroids (mainly dexamethasone) were also widely used to treat patients.\(^10\)

The first in vitro evidence of the efficacy of chloroquine on SARS-CoV-1 was published in 2004 by several Belgian and American teams.\(^11,\,12\) In 2014, Dutch scientists screened 348 FDA-approved molecules and identified 4 molecules effective on SARS-CoV-1, including chloroquine.\(^13\) In February 2020, Wang et al replicated these results in China on SARS-CoV-2 and clarified that chloroquine inhibited the virus both upon entry and during the intracellular stage.\(^9\) Several other studies have then reproduced the in vitro anti-viral effect on SARS-CoV-2 of chloroquine and its derivative, HCQ.\(^14,\,15\)

Different mechanisms have been proposed to explain the antiviral effect of chloroquine. This molecule is a weak base that alkalinizes intracellular acidic vesicles and interferes with microbes using the endolysosomal pathway, such as SARS-CoV-2.\(^16,\,17\) In addition, coronaviruses, including SARS-CoV-2, activate and utilize endoplasmic reticulum stress and replicate in a modified endoplasmic reticulum-derived compartment.\(^18\) Recent interactomics studies identified that chloroquine interferes with two non-structural viral protein-host protein interactions: nsps6 and the sigma-1 receptor, and Orf9c and the sigma-2 receptor.\(^14,\,15\) Strikingly, both these sigma receptors are known to act as endoplasmic reticulum stress “gatekeepers”.\(^19\) Furthermore, specific agonists of the sigma-1 receptor showed an anti-viral effect but antagonists of this receptor did not.\(^18\) Taken together, these results suggest that the antiviral effect of chloroquine on SARS-CoV-2 relies on several mechanisms but at least in part on agonist binding to sigma receptors, which is responsible for endoplasmic reticulum resistance to virus.

After the first Chinese publications about the antiviral effects of chloroquine and its derivatives against SARS-CoV-2, and our preliminary trial showing reducing viral shedding persistence when associated with azithromycin,\(^5\) we have adopted HCQ with azithromycin (AZ) to treat confirmed COVID-19 cases, despite other published or retracted studies claiming that this regimen would not be effective or toxic.\(^20–24\) Indeed, we have a long-time experience of the use of HCQ for the management of infectious diseases such as Coxiella burnetii and Tropheryma whipplei infections.\(^25,\,26\) With our experience on the follow-up of more than 2000 patients treated with long-term treatment (>1 year) of HCQ with a dosage of 600 mg/day, we reach a concentration of 1 μg/mL with a full safety. So, we chose this dosage for COVID-19 treatment.

More evidence for us to support HCQ-AZ use came with the demonstration of a synergistic effect in vitro of the HCQ-AZ combination on SARS-CoV-2 at concentrations compatible with that obtained in the human lung.\(^4\) In addition, both HCQ and AZ are known to have immunomodulator effects, which may prevent the “cytokine storm” of COVID-19. Also, in the context of COVID-19-associated pulmonary embolism, HCQ antithrombotic effects might have been of interest.\(^16\) Interestingly, although no statistically significant effect of HCQ was observed in large randomized studies,\(^27–30\) many observational studies consistently supported positive effects of HCQ early treatment.\(^7,\,31–33\)

In June 2020, we retrospectively reported the comparative clinical management of 3737 outpatients and inpatients treated with HCQ-AZ or other treatments. HCQ-AZ was associated with a decreased risk of transfer to the ICU or with death, a decreased risk of hospitalisation ≥10 days and shorter duration of viral shedding, with potential public health effects by reducing the duration of contagiousness.\(^34\)

However, outpatients and inpatients were mixed in this past study.\(^35\) Thereafter, we decided to analyse outpatient and inpatient cohorts separately. Accordingly, we have recently reported the data of 10,429 outpatients seen in our daycare hospital. The global mortality rate was 0.15%. It was 0.06% among the 8315 patients treated with HCQ-AZ in 2020.\(^35\)

Here, we report the management of 2111 inpatients treated in conventional hospital wards and observed by us, between 3 March and 31 December 2020, including only 673 previously reported.\(^34\) In comparison with previous studies, we have also analyzed here for the first time in our center the impact of zinc in combination with hydroxychloroquine and azithromycin,\(^36\) making the present study unique in several ways.

**Materials and Methods**

**Patients and Study Design**

Our study was conducted at the Institut Hospitalo-Universitaire (IHU) Méditerranée Infection (https://www.mediterra
nee-infection.com/), which is home to the infectious and tropical diseases department of the Assistance Publique-
Hôpitaux de Marseille (AP-HM), France. Our institute includes 75 hospital beds. Since the beginning of the outbreak, we performed early massive PCR screening both on patients suspected of having COVID-19 and their contacts. In addition, we proposed standardised treatment and follow-up for all individuals ≥18 years of age, with PCR-documented SARS-CoV-2 RNA from a nasopharyngeal sample in our outpatient ward. The most severe patients could be hospitalised in five different ways at our institute: 1) directly after screening in our day clinic, 2) outpatients initially followed in our day clinic and then requiring hospitalisation, 3) from the emergency department, 4) from other hospital wards or nursing homes, 5e) from intensive care units. Data were collected from the patients hospitalised between 3 March and 31 December 2020 and were retrospectively analysed.

Clinical, Biological and Radiological Data and Follow-Up
Demographic information (sex, age) and information on chronic conditions including cancer, diabetes mellitus, chronic heart disease, hypertension, chronic respiratory disease, obesity, hypothyroidism, asthma, obstructive sleep apnoea, and concomitant medications were recorded. The Charlson index was recorded, as previously described. Clinical symptoms, including anosmia, ageusia, rhinitis, fever, cough, dyspnoea and thoracic pain, were systematically documented. Clinical severity was assessed using the National Early Warning Score adapted to COVID-19 patients (NEWS-2) upon hospital admission. Three categories of clinical deterioration were defined, as previously described: low score (NEWS-2 = 0–4), medium score (NEWS-2 = 5–6), and high score (NEWS-2 ≥7).

We recorded biological parameters including haemoglobin, lymphocyte, eosinophil and platelet counts; fibrinogen; D-dimer and other coagulation factors; electrolytes; zinc; lactate dehydrogenase (LDH); creatine phosphokinase (CPK); and C-reactive protein. We had no data on vitamin D and nicotinamide. Viral load was analysed by qPCR from nasopharyngeal swabs on admission and during the follow-up, and an indirect immunofluorescence quantitative assay was used to assess the serological status against SARS-CoV-2. Viral culture was attempted for PCR-positive patients. A low dose CT-scan (LDCT) was proposed for all patients. Radiological lung lesions were classified into three categories: minimal, intermediate and severe involvement.

COVID-19 Management
The first-line treatment consisted of the combination of HCQ (200 mg of oral salt HCQ, three times daily for ten days) and AZ (500 mg on Day 1 followed by 250 mg daily for the next four days). This regimen was proposed as a standard treatment for all patients without contraindications to these drugs. As previously detailed, patients were informed of the off-label nature of the prescription of HCQ and AZ prior to receiving treatment. All patients underwent electrolyte analysis and an electrocardiogram (EKG) with corrected QT measurement (Bazett’s formula) before starting treatment. EKGs with any abnormalities were systematically referred to a cardiologist for further assessment. In addition, from March to June 2020, we systematically performed another EKG from Day 2 to Day 5. After analysis of the first results confirming the drug safety, we only performed a control of EKG (D2 to D5) for patients with previous EKG abnormalities, other drugs potentially increasing QT concomitantly used or in the cases of ionic disorders. From 15 April 2020 following the preliminary results in the international literature, we added the prescription of elemental zinc (15 mg, three times a day for 10 days).

In addition, broad-spectrum antibiotics (ceftriaxone or ertapenem) were included in the regimen for patients with pneumonia and/or NEWS scores ≥5. Since 5 April 2020, if they presented no contraindication, all patients were treated with an anticoagulant agent. The use of anticoagulant was decided according to the guidelines of the Société française d’anesthésie et de réanimation, with stratification according to the level of oxygen administration, the patient’s weight, D-dimers and fibrinogen dosage. For patients with a body mass index under 30 kg/m², we prescribed enoxaparin 4000 UI a day. If the body mass index was higher than 30 kg/m², or if high-flow oxygen was used, we prescribed enoxaparin 4000 UI bid or 6000 UI bid. In cases of hypercoagulability marked by D Dimers higher than 3 μg/mL or fibrinogen higher than 8 g/L, we prescribed tinzaparin 175 UI/kg/d or enoxaparin 100 UI/kg/bid (regardless of weight or level of oxygen administration). In cases of renal impairment, sodic or calcic heparin was used. If patients were already receiving treatment with an anticoagulant agent upon admission, treatment was continued or adjusted for heparin, according to the recommendations of the clinician in charge.
Standard care included systematic oxygen supplementation. From June 2020 we used dexamethasone 6 mg for ten days, for patients outside the acute phase of the disease who required increased oxygen. Finally, from 15 September 2020, we used high-flow oxygen therapy devices for patients who were not eligible for intensive care due to their age and/or their comorbidities and for whom transfer to the ICU was not possible.45

Outcomes
The primary outcome was six-week mortality from admission date. Regarding the endpoint for clinical efficacy treatment analysis, we used two methods. Firstly, we performed an “intention-to-treat” analysis. Secondly, as previously described, we analysed the per protocol outcome, selecting 72 hours after beginning the treatment for the evaluation.34 As a clinical outcome, we also evaluated transfer to the ICU as a secondary outcome.

Statistical Analysis
Categorical variables were presented as n (%). We used the Wilcoxon Mann Whitney test, Student’s t-test, χ2 test, or Fisher’s exact test to compare differences between groups of patients where appropriate. We performed multiple correspondence analysis (MCA) to investigate the associations between clinical data, biological data, radiological data, and the treatment received. In order to control for selection bias in comparing mortality between treatment groups, we used a propensity score weighting approach. The propensity score was calculated using a logistic regression with sex, age groups, NEWS-2 score, comorbidities and in-hospital treatment(s) (HCQ, AZ, zinc and/or corticosteroids when appropriate) as covariates. The predicted probabilities from the propensity-score model were then used to calculate the stabilised inverse-probability-weighting weights.46 The association between treatment groups and mortality was then assessed using weighted multivariable Cox models. Cox models were adjusted on the following variables: sex, age groups, NEWS-2 score, comorbidities and in-hospital treatment (HCQ, AZ, zinc and/or corticosteroids where appropriate). Adjusted hazard ratios with 95% confidence intervals were calculated from the Cox regression coefficient estimates. Sensitivity analyses were performed by assessing whether observed effects were reproducible and consistent across subgroups according to age class, sex, comorbidities, disease severity, co-medications, and reasons for non-treatment. A two-sided a value of less than 0.05 was considered to be statistically significant. Analyses were carried out using SAS 9.4 statistical software (SAS Institute, Cary, NC).

Ethics Statement
The data presented in this study were collected retrospectively from the routine care setting using the hospital’s electronic health recording system. In France, at the time the study was conducted, treatment of COVID-19 with HCQ was approved off-label for hospital delivery only. For all patients, HCQ-AZ was prescribed either during complete hospitalisation or at day-care clinic by one of the physicians, after collegial decision based on their analysis of the most recent scientific data available and after assessment of the benefit/harm ratio of the treatment. In line with the European General Data Protection Regulation No 2016/679, patients were informed of the potential use of their medical data and that they could refuse the use of their data. The analysis of collected data followed the MR-004 reference methodology registered under No. 2020–152 in the AP-HM register. The non-interventional, retrospective nature of the study was approved by our institute’s review board committee (Méditerranée Infection No.: 2021–015).

Results
Overall Characteristics of Patients
From 3 March to 31 December 2020, 2111 patients were hospitalised in our institute; 1155 (54.7%) of them were male. The median age was 67 years, 682 patients (32.3%) were over 75 years of age and 146 (6.9%) were over 89 years of age. Baseline clinical and biological characteristics are reported in Table 1, Tables S1 and S2, respectively. Most of the patients were hospitalised from the emergency department (1.114, 52.8%), 496 patients (23.5%) directly after evaluation in our day clinic. A total of 270 (12.8%) were first outpatients treated in our day clinic and then hospitalised, 193 patients (9.1%) came from other hospital wards and 38 patients (1.8%) were referred from the intensive care unit. A total of 1270
Table 1: Baseline Clinical Characteristics of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020

| Sex - men | All | %  | ICU Transfer | %  | Deaths | %  |
|-----------|-----|----|--------------|----|--------|----|
| n         | 2111|     | 271          | 73.8| 148    | 61.9|
| n         | 1154| 54.7| 200          | 73.8| 148    | 61.9|

| Age – mean (std) Q1-median-Q3 |
|-----------------------------|
| 65.8 (17.2) 55-67-79         |
| 63.2 (11.0) 56-64-72         |
| 81.2 (9.9) 75-83-89         |

| Age 18–29 | 67 | 3.2 | 1 | 0.4 | 0 | 0 |
| Age 30–39 | 118 | 5.6 | 6 | 2.2 | 0 | 0 |
| Age 40–49 | 168 | 8 | 27 | 10 | 2 | 0.8 |
| Age 50–59 | 380 | 18 | 60 | 22.1 | 7 | 2.9 |
| Age 60–69 | 451 | 21.4 | 91 | 33.6 | 22 | 9.2 |
| Age 70–79 | 401 | 19 | 73 | 26.9 | 56 | 23.4 |
| Age 80–89 | 380 | 18 | 13 | 4.8 | 105 | 43.9 |
| Age >89 | 146 | 6.9 | 0 | 0 | 47 | 19.7 |

| Charlson index V1\(^a\) - mean (std) Q1-median-Q3 |
|-------------------------------------------------|
| 4.5 (2.7) 2-4-6                                 |
| 4.0 (2.1) 2-4-5                                 |
| 6.9 (2.2) 5-7-8                                 |

| Charlson index V2\(^b\) - mean (std) Q1-median-Q3 |
|-------------------------------------------------|
| 1.4 (1.7) 0-1-2                                 |
| 1.3 (1.5) 0-1-2                                 |
| 2.4 (2.0) 1-2-3                                 |

| Chronic condition(s) |
|----------------------|
| Hypertension         |
| 956                  |
| 45.3                 |
| 129                  |
| 47.6                 |
| 150                  |
| 62.8                 |
| Diabetes mellitus    |
| 571                  |
| 27                   |
| 90                   |
| 33.2                 |
| 81                   |
| 33.9                 |
| Cancer disease       |
| 246                  |
| 11.7                 |
| 32                   |
| 11.8                 |
| 42                   |
| 17.6                 |
| Chronic respiratory diseases |
| 393                  |
| 18.6                 |
| 47                   |
| 17.3                 |
| 62                   |
| 25.9                 |
| Chronic heart diseases |
| 520                  |
| 24.6                 |
| 59                   |
| 21.8                 |
| 116                  |
| 48.5                 |
| Obesity              |
| 495                  |
| 23.4                 |
| 103                  |
| 38                   |
| 39                   |
| 16.3                 |
| Hypothyroidism       |
| 210                  |
| 9.9                  |
| 22                   |
| 8.1                  |
| 31                   |
| 13                   |
| Asthma               |
| 159                  |
| 7.5                  |
| 19                   |
| 7                    |
| 16                   |
| 6.7                  |
| Obstructive sleep apnoea |
| 112                  |
| 5.3                  |
| 21                   |
| 7.7                  |
| 15                   |
| 6.3                  |
| Other inflammatory disease |
| 97                   |
| 4.6                  |
| 12                   |
| 4.4                  |
| 16                   |
| 6.7                  |

| Medications |
|-------------|
| Metformin   |
| 336         |
| 15.9        |
| 50          |
| 18.5        |
| 34          |
| 14.2        |
| Beta blocking agents |
| 404         |
| 19.1        |
| 55          |
| 20.3        |
| 74          |
| 31.0        |
| Verapamil   |
| 28          |
| 1.3         |
| 3           |
| 1.1         |
| 4           |
| 1.7         |
| HMG CoA reductase inhibitors |
| 418         |
| 19.8        |
| 57          |
| 21.0        |
| 64          |
| 26.8        |
| Fibrates    |
| 26          |
| 1.2         |
| 3           |
| 1.1         |
| 6           |
| 2.5         |
| Dihydropyridine derivatives |
| 557         |
| 26.4        |
| 89          |
| 32.8        |
| 96          |
| 40.2        |
| Angiotensin II receptor blockers |
| 357         |
| 16.9        |
| 54          |
| 19.9        |
| 44          |
| 18.4        |
| ACE inhibitors |
| 251         |
| 11.9        |
| 34          |
| 12.5        |
| 30          |
| 12.6        |
| Tobacco consumption |
| 210         |
| 9.9         |
| 34          |
| 12.5        |
| 24          |
| 10.0        |

| Pulmonary CT-scanner |
|----------------------|
| Missing              |
| 208                  |
| 9.9                  |
| 16                   |
| 5.9                  |
| 33                   |
| 13.8                 |
| Normal               |
| 229                  |
| 10.8                 |
| 10                   |
| 3.7                  |
| 13                   |
| 5.4                  |
| Minimal              |
| 496                  |
| 23.5                 |
| 22                   |
| 8.1                  |
| 31                   |
| 13                   |
| Intermediate         |
| 717                  |
| 34                   |
| 90                   |
| 33.2                 |
| 69                   |
| 28.9                 |
| Severe               |
| 461                  |
| 21.8                 |
| 133                  |
| 49.1                 |
| 93                   |
| 38.9                 |

| Clinical symptoms |
|--------------------|
| Fever              |
| 601                 |
| 28.5                |
| 112                 |
| 41.3                |
| 67                  |
| 28                  |
| Cough              |
| 1023                |
| 48.5                |
| 146                 |
| 53.9                |
| 79                  |
| 33.1                |
| Rhinitis            |
| 127                 |
| 6                   |
| 8                   |
| 3                   |
| 1.3                 |

(Continued)
(60.2%) patients received the combination of HCQ-AZ. Of the 841 patients not treated with this combination, 529 patients (62.9%) had a contraindication, the treatment was not proposed by the physician for 251 patients (29.9%), 33 refused the treatment (3.9%), and data were not available for 28 patients (3.3%) (Table 2). In addition, 1302 (61.7%) patients were treated with zinc and 530 (25.1%) patients received dexamethasone.

**Clinical, Biological and Radiological Characteristics**

Underlying conditions and clinical symptoms are comprehensively described in Table 1. The mean Charlson index was 4.5 (±2.7). Most of the patients (796, 37.7%) had a NEWS-2 score ≥7 at the admission. A cough was the most frequent symptom (1023, 48.5%), followed by dyspnoea (942, 44.6%), fever (601, 28.5%), anosmia (258, 12.2%), ageusia (255, 12.1), and thoracic pain (942, 44.6%).

**Table 2 COVID-19 Hospitalized Patients Not Prescribed with Hydroxychloroquine and Azithromycin Combination (n = 841), Marseille, France, 2020**

| Treatments                  | n   | %     |
|-----------------------------|-----|-------|
| HCQ-AZ                      | 1270| 60.2  |
| Zinc                        | 1302| 61.7  |
| Dexamethasone               | 530 | 25.1  |

**Notes:** a Charlson index with age. b Charlson index without age.
12.1%), thoracic pain (172, 8.1%) and rhinitis (127, 6%). Patients’ biological characteristics upon admission of patients are comprehensively detailed in Table 3. The QT value was higher in the “No HCQ+AZT” (419.4 ms ±40.2) rather than in HCQ-AZ group (400.5 ms ±35.6). The multiple correspondence analysis (MCA) allowed for the identification of different groups of patients depending on the outcome and highlighted the main clinical, biological and radiological involvement associated with death (Figure 1).

Adverse Events Associated with Treatments
We listed 224 adverse events (Table 3). All adverse events were mild and included mostly gastrointestinal symptoms (74 cases of diarrhoea, 35 cases of nausea/vomiting and 29 cases of abdominal pain). We paid specific attention to QTc prolongation, which was observed in 38 patients (1.8%). Among them, only 11 patients had a QT > 500ms (0.52%). Among the 27 patients with QT < 500 ms, 13 patients (0.62%) had a QT expansion higher than 60 ms and 14 lower (0.66%). Thirty patients were treated with combination HCQ-AZ, 7 with AZ and 1 with HCQ. No cases of torsade de pointe or sudden death were observed.

Clinical outcomes
Of the 2111 hospitalised patients, 271 (12.8%) were transferred into ICU (male, 73.8%). The mean age was 63.2 (±11.0) years old (Table 1, Figure S1). A total of 239/2111 (11.3%) patients, including those who were transferred to the ICU, died within six weeks (male, 61.9%). Their mean age was 81.2 (±9.9) years old. Almost two-thirds of patients with a fatal outcome were 80 years of age or older (152 patients, 63.6%, Tables 1 and S1). Nine patients with a fatal outcome were under 60 years old. Of these nine patients, six had severe underlying conditions: two had Down’s Syndrome with restrictive pulmonary syndrome, one had a mislabelled mental disability and chronic pulmonary insufficiency, one had late stage multiple sclerosis rendering him bedridden, one had a late stage inflammatory neurological disease, and one patient suffered from vasculitis, cardiomyopathy, renal chronic insufficiency, diabetes mellitus and chronic obstructive

| Table 3 List of Adverse Events (n = 224) Among 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020 | n   | %    |
|-----------------------------------------------|-----|------|
| At least one adverse event                     | 224 | 10.6 |
| Diarrhoea                                      | 74  | 3.51 |
| Prolonged QTc                                  | 38  | 1.8  |
| -QT > 500 ms                                   | 11  | 0.52 |
| -Expansion > 60 ms and QT < 500 ms             | 13  | 0.62 |
| -Expansion < 60 ms and QT < 500 ms             | 14  | 0.66 |
| Nausea/vomiting                                | 35  | 1.66 |
| Abdominal pain/other digestive troubles        | 29  | 1.37 |
| Acute renal failure                            | 21  | 0.99 |
| Cytolysis/cholestasis                          | 20  | 0.95 |
| Neuropsychiatric signs (mood disorder, insomnia, nervousness) | 17  | 0.81 |
| Skin disorders                                 | 16  | 0.76 |
| Oral candidiasis                               | 14  | 0.66 |
| Headache                                       | 13  | 0.62 |
| Anorexia                                       | 12  | 0.57 |
| Fainting                                       | 9   | 0.43 |
| Blurred vision and other visual disturbance    | 5   | 0.24 |
| Dizziness                                      | 4   | 0.19 |
| Palpitations/tachycardia                       | 4   | 0.19 |
| Paraesthesia                                   | 2   | 0.09 |
| Trembling                                      | 1   | 0.05 |
pulmonary disease. Only three patients who died had only moderate underlying conditions: one patient was a 49-year-old migrant with poorly stabilised type 1 diabetes, one 54-year-old patient was morbidly obese, and one 59-year-old patient had hypertension.

No patients under the age of 39 died, and the mortality rate was 1.2% for the 40–49 age group, 1.8% for 50–59, 4.9% for 60–69, 14% for 70–79, 27.6% for 80–89 and 32.2% for patients over the age of 89. Interestingly, the 90-day mortality rate of patients hospitalised in our institute was lower than national data in all age groups for the period from 1 March to 15 June 2020 (Figure S2). Finally, mortality rates differed significantly depending on the mode of admission in our institute (2.2% for those who were first outpatients and were then hospitalized; 4.6% for patients who were directly hospitalized from our day clinic; 10.4% for patients transferred from other wards, and 17.1% for patients hospitalized from the emergency department (Table S1)).

**HCQ-AZ Combination**

The duration of hospitalization has been significantly shorter in the HCQ-AZ group (6.6 days vs 7.4 days in the No HCQ-AZ group, p < 0.001). The virus load at inclusion was not statistically different between the “HCQ-AZ” (24.4 ±5.3 CT) and the “No HCQ-AZ” groups (24.5 ± 5.7 CT). The six-week mortality rate of patients treated with combination of HCQ-AZ was significantly lower than patients treated with other regimen whether in intention-to-treat (7.3% versus 17.4%, p < 0.001) or per protocol including patients treated ≥3 days (5.9% versus 16.6%, p < 0.001). In a weighted multivariate Cox proportional hazards model, HCQ-AZ was an independent protective factor against death (death hazard ratio (HR) 0.68, 95% confidence interval (95% CI) (0.52–0.88)) (Figures 2–3, Tables 4–5). This effect was consistent for all subgroups of age, comorbidities, severity of the disease and comedications with zinc or corticosteroids (Figure 2). Reasons for non-treatment (contraindication, non-proposition and refusal) were not confounding factors, as subgroup analyses excluding or including only these patients highlighted a similar protective effect (Figure 2). This independent protective factor was confirmed in a 10-year age-stratified multivariable Cox proportional-hazards models from 55 to >80 years with hazard ratio ranging from 0.12 to 0.97 (Figure S3).
Comparing the 1302 patients treated with zinc to the 809 other patients not treated with zinc, using propensity weighted analysis, we did not demonstrate a reduction in death independently of age, comorbidities, severity of the diseases and other treatment (Figure S4 Table S3). Nevertheless, subgroup analyses evidenced that zinc was an independent protective factor against death among patients treated with HCQ-AZ without dexamethasone (n = 1018, death hazard ratio (HR), 0.39, 95% CI 0.23–0.67, p = 0.0011; weighted multivariate Cox proportional hazards model) (Figure 4) and a trend for beneficial effect was observed in those treated with AZ only (n = 435, death hazard ratio (HR), 0.64, 95% CI 0.39–1.06, p = 0.0813).

Dexamethasone
Patients treated with dexamethasone were significantly older, more frequently male, had more severe symptoms and were significantly more likely to die (Table S4). Using a propensity weighted score to compare them, corticosteroids remained an independent factor associated with death for patients with CRP <100 mg/L (death
hazard ratio (HR) 3.36, 95% confidence interval (2.09–5.40)) (Table S4, Figure S5). Conversely, for patients with CRP > 100mg/L, no difference in death outcome was observed between patients treated with or without corticosteroids (Table S6, Figure S6).

Table 4 Comparison of Treatment Groups (HCQ-AZ vs No HCQ-AZ, n = 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020)

|                        | Unweighted Sample | Propensity Weighted Sample |
|------------------------|-------------------|---------------------------|
|                        | HCQ-AZ N = 1270   | No HCQ-AZ N = 841         |
|                        |                   | P*                        |
|                        |                   | HCQ-AZ N = 1270           | No HCQ-AZ N = 841 |
|                        |                   | P*                        |
| Age mean (std)         | 63.0 (16.7)       | 70.0 (17.2)               | <0.001            | 65.6 (15.0)       | 65.1 (21.4)       | 0.558             |
| Men (%)                | 54.8%             | 54.5%                     | 0.876             | 55.0%             | 55.6%             | 0.778             |
| NEWS score             |                   |                           |                   |                   |                   |                   |
| 0–4                    | 38.3%             | 29.5%                     | <0.001            | 35.0%             | 35.5%             | 0.963             |
| 5–6                    | 27.8%             | 27.0%                     | 27.3%             | 26.8%             |                   |                   |
| >6                     | 33.9%             | 43.5%                     | 37.7%             | 37.7%             |                   |                   |
| Comorbidities          |                   |                           |                   |                   |                   |                   |
| Hypertension           | 40.3%             | 52.8%                     | <0.001            | 45.0%             | 44.8%             | 0.912             |
| Diabetes mellitus      | 26.0%             | 28.7%                     | 0.176             | 26.9%             | 26.5%             | 0.861             |
| Cancer disease         | 11.3%             | 12.2%                     | 0.489             | 12.0%             | 12.2%             | 0.853             |
| Chronic respiratory diseases | 16.2%             | 22.2%                     | 0.001             | 18.6%             | 19.0%             | 0.820             |
| Chronic heart diseases | 17.4%             | 35.6%                     | <0.001            | 24.4%             | 24.5%             | 0.980             |
| Obesity                | 22.9%             | 24.3%                     | 0.476             | 23.2%             | 23.3%             | 0.969             |
| Hypothyroidism         | 8.4%              | 12.2%                     | 0.004             | 9.7%              | 9.6%              | 0.912             |
| Asthma                 | 7.3%              | 7.8%                      | 0.655             | 7.6%              | 7.8%              | 0.875             |
| Other inflammatory disease | 3.9%             | 5.7%                      | 0.047             | 4.6%              | 4.6%              | 0.977             |
| Treatments (other than HCQ-AZ) |         |                           |                   |                   |                   |                   |
| Zinc                   | 57.2%             | 68.5%                     | <0.001            | 61.9%             | 61.6%             | 0.888             |
| Corticosteroids        | 19.8%             | 33.1%                     | <0.001            | 25.5%             | 25.6%             | 0.970             |

Note: *Chi-square/Fisher’s exact or Student’s t-test where appropriate.
High-Flow Oxygen Therapy
Fifty-six elderly patients who were not eligible for transfer to the ICU due to their age and comorbidities were treated in our institute using high-flow oxygen therapy. The mean age of these patients was 80.5 years (median 82.5) and 32 (57.1%) were male. These patients suffered from several underlying conditions (mean Charlson index: 6.8). Upon admission to our wards, clinical involvement was severe, with 80.4% of the patients having NEWS-2 score ≥7 (Table S7). Ultimately, 19 patients (33.9%) were weaned off HFNO and survived thanks to this technique.

Discussion
In our institute, and during the first year of the SARS-CoV-2 pandemic, we implemented a widespread strategy of PCR screening of patients and early treatment. This led us to perform more than 600,000 PCRs, for 400,000 patients, of which 45,000 were positive. More than 20,000 were treated in our institute as inpatients or outpatients.38

When we have reported our 2020 outpatients’ study,35 the need for early treatment using HCQ was demonstrated on a large Iranian outpatient study (28,759 outpatients) and a Saudi Arabian study (5541 outpatients).31,32 Moreover, the setting of a daycare hospital allowing for an early access to healthcare may have contributed to the low fatality rate in our cohort. Indeed, patients admitted from the emergency ward had a 10-fold higher risk of death compared to patients initially treated as outpatients in our center (17 versus 2%), and a 4-fold higher risk compared to patients directly admitted the day they come to the daycare hospital (17 vs 5%).

Herein, in a monocentric cohort of 2111 patients hospitalized in 2020, we noted a beneficial effect of HCQ-AZ after controlling for age, comorbidities and severity of the disease. This effect was consistent for all subgroups analyzed, and
reasons for non-treatment (contraindication, non-proposition by the physician and refusal by the patient) were not confounding factors, as shown with subgroup analyses. Our work was performed on hospitalized patients treated in a unique institute using drugs at a dosage already used in other indications. For the first time in our center, we evidenced the beneficial effect of zinc when added to HCQ and AZ. We performed a stringent follow-up to assess the condition of patients and consequently we are certain of the veracity of these observations. Overall, the data set contains 1.7 million items that is accessible to everyone (10.35081/mm67-dj74). This large cohort allows us to confirm the absence of significant cardiotoxicity when HCQ and AZ are used in hospitalized patients carefully using a standardized protocol. Indeed, we did not observe any torsades de pointe nor sudden death.

In this study, undoubtedly, the mortality rate that we observed was lower than in most studies including only hospitalized patients.\textsuperscript{20,27–29} The risk of death in patients was the same as that previously described in other series, and patients over 80 years of age or with severe underlying conditions are particularly vulnerable. Conversely, the risk of death is extremely rare in patients under the age of 60 without comorbidities, as soon as they have access to care.

However, the use of HCQ-AZ for COVID-19 treatment has resulted in academic discord and even political issues.\textsuperscript{47} Passionate debates have occurred in the media and scientific journals about the possible toxicity of CQ or HCQ.

Moreover, the discussion about the need randomized controlled trials (RCTs) to support therapeutic choice and public health decision is an issue and may be considered as limitation of our study. However, a Cochrane Library publication stated that observational studies and randomized controlled trials (RCTs) should give the same results.\textsuperscript{48} Interestingly, most observational studies reporting that early HCQ with or without treatment shows positive results, whereas it is not effective when used very late and/or with high dosage over a long period. On the other side, studies based on big data have not shown such results.

Anyway, our goal here is not to be part of the discussion about RCTs versus observational studies. We think that controversies are part of science and that such monocentric experience can help with the management of future outbreaks or new outbreaks linked to COVID-19. When patients are grouped in cohorts, daily observations allow standard care to be adjusted, such as the early use of anticoagulation for COVID-19 in patients. Finally, the equipment in the HFNO allowed us to propose a therapeutic treatment to patients who were not eligible for transfer to the ICU due to their age or comorbidities,

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{Kaplan–Meier curve of survival according to treatment groups (propensity weighted sample, \textit{n}=1018 COVID-19 patients treated with HCQ-AZ ± zinc (no corticosteroid) in Marseille, France 2020). Log rank test: \textit{p}=0.0011. Adjusted hazard ratio: 0.39 0.23–0.67 (\textit{p}<0.001).}
\end{figure}
which enabled us to save 19 lives in 2020. For us, this series also supports that protocols and recommendations must be established and modified as knowledge of the disease increases. This approach is difficult in randomised trials.

Finally, we did not find any benefit of corticosteroids, as reported in the Recovery trial,\textsuperscript{10} and which may have been part of the basic recommendations on the treatment of this disease. The Simpson effect cannot be excluded in the evaluation of corticosteroids, because the patients treated with corticosteroids had significantly more severe condition and were hospitalized at different stages of the disease.\textsuperscript{10,49} However, caution is essential, especially in the acute phase of the disease or when there is no inflammatory syndrome during which the effect may be harmful.

In meta-analyses, the choice of the selected studies influences dramatically the results that may be biased.\textsuperscript{50} We continue to believe that monocentric studies are highly valuable due to the homogeneity of standard care (the “in our hands” phenomenon). Moreover, the concentration in any given institute leads to a progression in the quality of care, which is linked to medical experience, the importance of which should not be neglected.

**Conclusion**

We think that drug repurposing or repositioning is an important field in drug discovery that identifies new therapeutic possibilities for existing drugs. In addition to HCQ-AZ, other possible drug candidates for Covid-19 treatment might be identified.\textsuperscript{51} Also, access to care and the quality of care remains a major element in patient care and observation remains a major element in reflecting on that care, particularly when it comes to new diseases. Our series focused on patients hospitalized in 2020, at which time there were no credible oral therapeutic alternatives. Since then, other oral alternatives have been proposed (paxlovid, molnupiravir …).\textsuperscript{52} However, based on our experience and the results reported here, we will continue to use HCQ-AZ in hospitalized COVID-19 patients. We will continue our observations in the SARS-Cov 2 variants,\textsuperscript{53} vaccination and post-vaccination era.\textsuperscript{54}

**The IHU Task Force Includes Clinicians, Microbiologists, Statisticians, Pharmacologists, Hematologists, Epidemiologists Who Contributed to the Care and the Diagnostic in the Patients of This Cohort, and to the Writing of This Paper and/or The Care of the Patients**

Sophie Amrane, Camille Aubry, Cyril Berenger, Anne Darmon, Barbara Doudier, Pierre Dudouet, Justine Raclot, Piseth Seng, Stéphanie Gentile, Sylvie Arlotto, Audrey Giraud-Gatineau, Laurence Camoin-Jau, Philippe Gautret, Herve Tissot-Dupont, Florence Fenollar, Baptiste Maille, Alexis Jacquier, Stéphane Honore, Yolande Obadia, Andreas Stein.

**Acknowledgments**

We are thankful to all the medical students from Aix Marseille University, all the nurses, laboratory staff, administrative, technical and security staff of the Assistance Publique-Hôpitaux de Marseille and IHU Méditerranée Infection, as well as all the volunteer medical doctors for their help.

**Funding**

This work was funded by ANR “Investissements d’avenir”, Méditerranée infection 10-IAHU-03, and was also supported by Région Provence-Alpes-Côte d’Azur. This work had received financial support from the Fondation Méditerranée Infection.

**Disclosure**

Prof. Dr Didier Raoult reports personal fees from Scientific board member of Eurofins company, Founder and shareholder of a microbial culture company (Culture Top), received personal fees from Hitachi High-Technologies Corporation, Tokyo, Japan, from 2018 to 2020, Founder and shareholder of Biotechnology “Techno-jouvence”, Founder and shareholder of a Biotech company “Gene and Green TK, Founder and shareholder of rapid diagnosis of infectious diseases company “Pocramé”, outside the submitted work. The authors declare no other competing interests.
Funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

References

1. Johns Hopkins University. Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available from: https://coronavirus.jhu.edu/map.html. Accessed January 17, 2022.

2. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends*. 2020;14(1):72–73. doi:10.5898/bst.2020.01047

3. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov*. 2020;6:16. doi:10.1038/s41421-020-0156-0

4. Andreani J, Le Bideau M, Duflot I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *Microb Pathog*. 2020;145:104228. doi:10.1016/j.micpath.2020.104228

5. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020;56:105949. doi:10.1016/j.ijantimicag.2020.105949

6. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. *Travel Med Infect Dis*. 2020;34:101663. doi:10.1016/j.tmaid.2020.101663

7. Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. *Travel Med Infect Dis*. 2020;35:101738. doi:10.1016/j.tmaid.2020.101738

8. Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. *N Engl J Med*. 2020;382:1787–1799. doi:10.1056/NEJMoa2001282

9. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet Infect Dis*. 2020;39:1569–1578.

10. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson J, Mahtm M, Bell JL et al. Dexamethasone in hospitalized patients with COVID-19. *N Engl J Med*. 2021;384(8):693–704. doi:10.1056/NEJMoa212436

11. Keyaerts E, Vigen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. *Biochem Biophys Res Commun*. 2004;323(1):264–268. doi:10.1016/j.bbrc.2004.08.085

12. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virol J*. 2005;2:69. doi:10.1186/1743-422X-2-69

13. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture. *Antimicrob Agents Chemother*. 2014;58(8):4875–4884. doi:10.1128/AAC.03011-14

14. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature*. 2020;583(7816):459–468. doi:10.1038/s41586-020-2286-9

15. Gordon DE, Hiatt J, Bouhaddou M, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. *Science*. 2020;370(6521):eaee9403. doi:10.1126/science.aae9403

16. Gautret P, Million M, Jarrot PA, et al. Natural history of COVID-19 and therapeutic options. *Expert Rev Clin Immunol*. 2020;16(12):1159–1184. PMID: 33356661. doi:10.1080/1744666X.2021.1847640

17. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? *Int J Antimicrob Agents*. 2020;55(5):105938. doi:10.1016/j.ijantimicag.2020.105938

18. Ostrov DA, Bluhm AP, Clemen N, Raoult D. Clinical and microbiologic effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. *Travel Med Infect Dis*. 2020;35:101738. doi:10.1016/j.tmaid.2020.101738

19. Self WH, Seither LM, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. *JAMA*. 2020;324:2165. doi:10.1001/jama.2020.22240

20. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. *N Engl J Med*. 2020;382(25):2411–2418. doi:10.1056/NEJMoa2012410

21. Lagier JC, Raoult D. Whipple’s disease and *Tropheryma whipplei* infections: when to suspect them and how to diagnose and treat them. *Curr Opin Infect Dis*. 2018;31(4):463–470. doi:10.1097/QCO.0000000000000489

22. Meloetote C, Million M, Raoult D. New insights in *Coxiella burnetii* infection: diagnosis and therapeautic update. *Expert Rev Anti Infect Ther*. 2020;18(1):75–86. PMID: 31782315. doi:10.1080/14787271.2020.1699055

23. Fried MW, Crawford JM, Mopar AN, et al. Patient characteristics and outcomes of 11 721 patients with coronavirus disease 2019 (COVID-19) hospitalized across the United States. *Clin Infect Dis*. 2021;72(10):e558–e565. doi:10.1093/cid/ciaa1268

24. Skipper CP, Postich KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. *Ann Intern Med*. 2020;173:623e31. doi:10.7326/M20-4207

25. Boulware DR, Pullen MF, Bangdiwala A, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19. *N Engl J Med*. 2020;383:571e25. doi:10.1056/NEJMoa2016638
Therapeutics and Clinical Risk Management

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal

30. Ader F, Peiffer-Smadja N, Poissy J, et al. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. *Clin Microbiol Infect.* 2021;27:1826–1837. doi:10.1016/j.cmi.2021.05.020

31. Sulaiman T, Mohana A, Alawdah L, et al. The effect of early hydroxychloroquine-based therapy in COVID-19 patients in ambulatory care settings: a nationwide prospective cohort study. *medRxiv.* 2020. doi:10.1101/2020.09.09.20184143

32. Mokhtar M, Mohraz M, Gouya MM, et al. Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting. *Int Immunopharmacol.* 2021;96:107636. PMID: 34015598; PMCID: PMC8023208. doi:10.1016/j.intimp.2021.107636

33. Global HCQ/CQ studies. Available from: https://c19study.com. Accessed May 24, 2022.

34. Lagier JC, Million M, Gautret P, et al. Outcomes of 3737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. *Travel Med Infect Dis.* 2020;36:101791. doi:10.1016/j.tmaid.2020.101791

35. Million M, Lagier JC, Tissot-DuPont H, et al. Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients. *Rev Cardiovasc Med.* 2021;22(3):1063–1072. PMID: 34565108. doi:10.3808/rcm.r2203116

36. Carlucci PM, Ahuja T, Petrelli C, Rajagopalan H, Jones S, Rahimian J. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. *J Med Microbiol.* 2020;69(10):1228–1234. PMID: 32930657; PMCID: PMC7660893. doi:10.1099/jmm.0.001250

37. Amrane S, Tissot-DuPont H, Doudier B, et al. Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, January 31st to March 1st, 2020: a respiratory virus snapshot. *Travel Med Infect Dis.* 2020;36:101632. doi:10.1016/j.tmaid.2020.101632

38. Brouqui P, Drancourt M, Raoult D. On behalf of the ihu task force. COVID-19 management at ihu méditerranée infection: a one-year experience. *J Clin Med.* 2021;10(13):2881. PMID: 34209634; PMCID: PMC8268723. doi:10.3390/jcm10132881

39. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. *J Clin Epidemiol.* 1994;47(11):1245–1251. doi:10.1016/0895-4356(94)90129-5

40. Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-The experience in Sichuan Province, China. *Intensive Care Med.* 2020;46:357–360. doi:10.1007/s00134-020-05954-2

41. Edouard S, Colson P, Melenotte C, et al. Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France. *Eur J Clin Microbiol Infect Dis.* 2021;40(2):361–371. doi:10.1007/s10096-020-04104-2

42. Wurtz N, Penant G, Jardot P, Duclos N, La Scola B. Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile. *Eur J Clin Microbiol Infect Dis.* 2021;40(3):477–484. PMID: 33389257. doi:10.1007/s10096-020-04106-0

43. Leger T, Jacquier A, Barral PA, et al. Low-dose chest CT for diagnosing and assessing the extent of lung involvement of SARS-CoV-2 pneumonia using a semi quantitative score. *PLoS One.* 2020;15(11):e0241407. doi:10.1371/journal.pone.0241407

44. Susen S, Tacquard CA, Godon A, Mansour A, Garrigue D, Nguyen P, Godier A, Testa S, Levy JH, Albaladejo P, Gruel Y; GIHP and GFHT. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. *Crit Care.* 2020 Jun 19;24(1):364. doi:10.1186/s13054-020-03000-7. PMID: 32560658; PMCID: PMC7303590.

45. Lagier JC, Amrane S, Mailhe M, et al. High-flow oxygen therapy in elderly patients infected with SARS-CoV2 with a contraindication for transfer to an intensive care unit: a preliminary report. *Int J Infect Dis.* 2021;108:1–3. doi:10.1016/j.ijid.2021.03.087

46. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivar Behav Res.* 2011;46(3):399–422. doi:10.1080/00273171.2011.568786

47. Gautret P, Raoult D. Nullane salus extra ecclesiæ. *New Microbes New Infect.* 2020;37:100714. doi:10.1016/j.nmni.2020.100714

48. Anglemeyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. *Cochrane Database Syst Rev.* 2014(4):MR000034. doi:10.1002/14651858.MR000034.pub2

49. Janket SJ, Ackerson LK, Diamandis E. Simpson’s paradox in proof-of-concept studies. *Nat Med.* 2019;25(1640). doi:10.1038/s41591-019-0624-y

50. Million M, Dudouet P, Chabrière E, et al. Predictive factors of clinical assays on hydroxychloroquine for COVID-19 mortality during the first year of the pandemic: a meta-synthesis. *Afr J Clin Exp Microbiol.* 2022;23:1–13. doi:10.4314/ajcem.v23i1.1

51. Aherfi S, Pradines B, Devaux C, et al. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. *Future Microbiol.* 2021;16:1341–1370. PMID: 34755538; PMCID: PMC8579950. doi:10.2217/fmb-2021-0019

52. Hayashi K. Molnupiravir might be dangerous without clarification of its indications. *BMJ.* 2022;377:o1030. doi:10.1136/bmj.o1030

53. Colson P, Fournier PE, Chauvet H, et al. Analysis of SARS-CoV-2 variants from 24,181 patients exemplifies the role of globalization and zoonosis in pandemics. *Front Microbiol.* 2022;12:78623. PMID: 35197938; PMCID: PMC8559183. doi:10.3389/fmicb.2021.78623

54. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet.* 2022;399:924–944. PMID: 35202601. doi:10.1016/S0140-6736(22)00152-0